Assessment Following Total Neoadjuvant Therapy for Rectal Cancer

Abstract

Over the past decade, total neoadjuvant therapy (TNT) has become increasingly accepted and adopted as the initial treatment for locally advanced rectal cancer. Following TNT, treatment response is assessed using three main modalities: clinical exam, endoscopy, and imaging. In this article, we summarize the known advantages, disadvantages, and controversies associated with each method of assessment.

Keywords

rectal cancer - total neoadjuvant therapy - watch and wait

Publikationsverlauf

Artikel online veröffentlicht:
07. Januar 2026

• References

• 1 Cercek A, Roxburgh CSD, Strombom P. et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4 (06) e180071
• 2 Hilty Chu BK, Loria A, Dhimal T. et al. The rise of patients declining rectal cancer surgery in the era of total neoadjuvant therapy. Ann Surg Oncol 2024; 31 (12) 7798-7806
• 3 Cerdan-Santacruz C, São Julião GP, Vailati BB, Corbi L, Habr-Gama A, Perez RO. Watch and wait approach for rectal cancer. J Clin Med 2023; 12 (08) 2873
• 4 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
• 5 Chadi SA, Malcomson L, Ensor J. et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (12) 825-836
• 6 Cerdán-Santacruz C, Vailati BB, São Julião GP, Habr-Gama A, Perez RO. Watch and wait: why, to whom and how. Surg Oncol 2022; 43: 101774
• 7 Habr-Gama A, de Souza PM, Ribeiro Jr U. et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998; 41 (09) 1087-1096
• 8 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
• 9 Williams H, Lee C, Garcia-Aguilar J. Nonoperative management of rectal cancer. Front Oncol 2024; 14: 1477510
• 10 National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer
• 11 Hupkens BJP, Martens MH, Stoot JH. et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum 2017; 60 (10) 1032-1040
• 12 Deidda S, Spolverato G, Capelli G. et al. Limits of clinical restaging in detecting responders after neoadjuvant therapies for rectal cancer. Dis Colon Rectum 2023; 66 (07) 957-964
• 13 Maas M, Lambregts DM, Nelemans PJ. et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 2015; 22 (12) 3873-3880
• 14 Ogura A, Chino A, Konishi T. et al. Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. Int J Colorectal Dis 2015; 30 (03) 367-373
• 15 van der Sande ME, Maas M, Melenhorst J, Breukink SO, van Leerdam ME, Beets GL. Predictive value of endoscopic features for a complete response after chemoradiotherapy for rectal cancer. Ann Surg 2021; 274 (06) e541-e547
• 16 Brady JT, Wright JP, Davids JS. et al. The impact of nonoperative management of rectal cancer on colon and rectal surgery residents in the United States. Colorectal Dis 2025; 27 (05) e70125
• 17 Gollub MJ, Costello JR, Ernst RD. et al. A primer on rectal MRI in patients on watch-and-wait treatment for rectal cancer. Abdom Radiol (NY) 2023; 48 (09) 2836-2873
• 18 Patel UB, Blomqvist LK, Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response–the MERCURY experience. AJR Am J Roentgenol 2012; 199 (04) W486-95
• 19 Hall WA, Li J, You YN. et al. Prospective correlation of magnetic resonance tumor regression grade with pathologic outcomes in total neoadjuvant therapy for rectal adenocarcinoma. J Clin Oncol 2023; 41 (29) 4643-4651
• 20 Mandard AM, Dalibard F, Mandard JC. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73 (11) 2680-2686
• 21 El Khababi N, Beets-Tan RGH, Tissier R. et al; Rectal MRI Study Group. Sense and nonsense of yT-staging on MRI after chemoradiotherapy in rectal cancer. Colorectal Dis 2023; 25 (09) 1878-1887
• 22 Nahas SC, Nahas CSR, Cama GM. et al. Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer. Abdom Radiol (NY) 2019; 44 (11) 3632-3640
• 23 Bates DDB, Homsi ME, Chang KJ, Lalwani N, Horvat N, Sheedy SP. MRI for rectal cancer: staging, mrCRM, EMVI, lymph node staging and post-treatment response. Clin Colorectal Cancer 2022; 21 (01) 10-18
• 24 Lalwani N, Bates DDB, Arif-Tiwari H, Khandelwal A, Korngold E, Lockhart M. Baseline MR staging of rectal cancer: a practical approach. Semin Roentgenol 2021; 56 (02) 164-176
• 25 Lee S, Kassam Z, Baheti AD. et al. Rectal Cancer Lexicon 2023 Revised and Updated Consensus Statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel. Abdom Radiol (NY) 2023; 48 (09) 2792-2806
• 26 Doyon F, Attenberger UI, Dinter DJ, Schoenberg SO, Post S, Kienle P. Clinical relevance of morphologic MRI criteria for the assessment of lymph nodes in patients with rectal cancer. Int J Colorectal Dis 2015; 30 (11) 1541-1546
• 27 Mizukami Y, Ueda S, Mizumoto A. et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg 2011; 35 (04) 895-899
• 28 Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104 (01) 66-73
• 29 Restivo A, Zorcolo L, Cocco IM. et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol 2013; 20 (03) 864-871
• 30 Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol 2020; 26 (44) 7022-7035
• 31 Morais M, Fonseca T, Melo-Pinto D. et al. Evaluation of ctDNA in the prediction of response to neoadjuvant therapy and prognosis in locally advanced rectal cancer patients: a prospective study. Pharmaceuticals (Basel) 2023; 16 (03) 427
• 32 Garlan F, Laurent-Puig P, Sefrioui D. et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res 2017; 23 (18) 5416-5425
• 33 Jia N, Sun Z, Gao X. et al. Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response. Front Genet 2019; 10: 470
• 34 Tie J, Wang Y, Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8 (346) 346ra92
• 35 Murahashi S, Akiyoshi T, Sano T. et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer 2020; 123 (05) 803-810
• 36 Bi F, Wang Q, Dong Q, Wang Y, Zhang L, Zhang J. Circulating tumor DNA in colorectal cancer: opportunities and challenges. Am J Transl Res 2020; 12 (03) 1044-1055
• 37 Wang Y, Yang L, Bao H. et al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med 2021; 18 (08) e1003741
• 38 Mögele T, Höck M, Sommer F. et al. Circulating tumor DNA for prediction of complete pathological response to neoadjuvant radiochemotherapy in locally advanced rectal cancer (NEORECT Trial). Cancers (Basel) 2024; 16 (24) 4173
• 39 Perez RO, Habr-Gama A, São Julião GP. et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks?. Int J Radiat Oncol Biol Phys 2012; 84 (05) 1159-1165
• 40 Fernandez LM, São Julião GP, Figueiredo NL. et al; International Watch & Wait Database Consortium. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol 2021; 22 (01) 43-50